newdrugapprovals.org
BioMarin gets US priority review for rare disease drug
31 may 2013 BioMarin will be celebrating news that regulators on both sides of the Atlantic have agreed to review Vimzin under accelerated review processes. Vimzin is an enzyme replacement therapy …